TrialAnnals of the rheumatic diseases2022

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.

Lars Erik Kristensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.